DUPILUMAB REDUCES SEVERE EXACERBATION RATE AND IMPROVES LUNG FUNCTION IN ADOLESCENT PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA: FROM THE LIBERTY ASTHMA QUEST STUDY.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      Dupilumab 200 mg reduced the annualized exacerbation rate by 46.4%, while dupilumab 300 mg did not show treatment effect vs PBO in adolescents, although the unadjusted exacerbation rate was 0.46 for dupilumab 300 mg and 0.76 for PBO. B CLINICAL IMPLICATIONS: b Dupilumab may benefit lung function and severe exacerbation rates in adolescents with uncontrolled moderate-to-severe asthma. [Extracted from the article]
    • Abstract:
      Copyright of CHEST is the property of American College of Chest Physicians and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • Full Text Word Count:
      1386
    • ISSN:
      0012-3692
    • Accession Number:
      10.1016/j.chest.2018.08.022
    • Accession Number:
      132238697
  • Citations
    • ABNT:
      MASPERO, J. et al. Dupilumab Reduces Severe Exacerbation Rate and Improves Lung Function in Adolescent Patients with Uncontrolled, Moderate-To-Severe Asthma: From the Liberty Asthma Quest Study. CHEST, [s. l.], v. 154, p. 25A–27A, 2018. DOI 10.1016/j.chest.2018.08.022. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=hch&AN=132238697. Acesso em: 3 dez. 2020.
    • AMA:
      MASPERO J, FITZGERALD M, PAVORD I, et al. Dupilumab Reduces Severe Exacerbation Rate and Improves Lung Function in Adolescent Patients with Uncontrolled, Moderate-To-Severe Asthma: From the Liberty Asthma Quest Study. CHEST. 2018;154:25A-27A. doi:10.1016/j.chest.2018.08.022
    • APA:
      MASPERO, J., FITZGERALD, M., PAVORD, I., WENZEL, S., ZHANG, B., MARONI, J., ROWE, P., AMIN, N., PIROZZI, G., RUDDY, M., AKINLADE, B., GRAHAM, N., & TEPER, A. (2018). Dupilumab Reduces Severe Exacerbation Rate and Improves Lung Function in Adolescent Patients with Uncontrolled, Moderate-To-Severe Asthma: From the Liberty Asthma Quest Study. CHEST, 154, 25A–27A. https://doi.org/10.1016/j.chest.2018.08.022
    • Chicago/Turabian: Author-Date:
      MASPERO, JORGE, MARK FITZGERALD, IAN PAVORD, SALLY WENZEL, BINGZHI ZHANG, JAMAN MARONI, PAUL ROWE, et al. 2018. “Dupilumab Reduces Severe Exacerbation Rate and Improves Lung Function in Adolescent Patients with Uncontrolled, Moderate-To-Severe Asthma: From the Liberty Asthma Quest Study.” CHEST 154 (October): 25A–27A. doi:10.1016/j.chest.2018.08.022.
    • Harvard:
      MASPERO, J. et al. (2018) ‘Dupilumab Reduces Severe Exacerbation Rate and Improves Lung Function in Adolescent Patients with Uncontrolled, Moderate-To-Severe Asthma: From the Liberty Asthma Quest Study’, CHEST, 154, p. 25A–27A. doi: 10.1016/j.chest.2018.08.022.
    • Harvard: Australian:
      MASPERO, J, FITZGERALD, M, PAVORD, I, WENZEL, S, ZHANG, B, MARONI, J, ROWE, P, AMIN, N, PIROZZI, G, RUDDY, M, AKINLADE, B, GRAHAM, N & TEPER, A 2018, ‘Dupilumab Reduces Severe Exacerbation Rate and Improves Lung Function in Adolescent Patients with Uncontrolled, Moderate-To-Severe Asthma: From the Liberty Asthma Quest Study’, CHEST, vol. 154, p. 25A–27A, viewed 3 December 2020, .
    • MLA:
      MASPERO, JORGE, et al. “Dupilumab Reduces Severe Exacerbation Rate and Improves Lung Function in Adolescent Patients with Uncontrolled, Moderate-To-Severe Asthma: From the Liberty Asthma Quest Study.” CHEST, vol. 154, Oct. 2018, p. 25A–27A. EBSCOhost, doi:10.1016/j.chest.2018.08.022.
    • Chicago/Turabian: Humanities:
      MASPERO, JORGE, MARK FITZGERALD, IAN PAVORD, SALLY WENZEL, BINGZHI ZHANG, JAMAN MARONI, PAUL ROWE, et al. “Dupilumab Reduces Severe Exacerbation Rate and Improves Lung Function in Adolescent Patients with Uncontrolled, Moderate-To-Severe Asthma: From the Liberty Asthma Quest Study.” CHEST 154 (October 2, 2018): 25A–27A. doi:10.1016/j.chest.2018.08.022.
    • Vancouver/ICMJE:
      MASPERO J, FITZGERALD M, PAVORD I, WENZEL S, ZHANG B, MARONI J, et al. Dupilumab Reduces Severe Exacerbation Rate and Improves Lung Function in Adolescent Patients with Uncontrolled, Moderate-To-Severe Asthma: From the Liberty Asthma Quest Study. CHEST [Internet]. 2018 Oct 2 [cited 2020 Dec 3];154:25A–27A. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=hch&AN=132238697